Evaxion Biotech A/S ADR (NASDAQ:EVAX)’s traded shares stood at 0.49 million during the last session, with the company’s beta value hitting -0.28. At the close of trading, the stock’s price was $2.58, to imply a decrease of -6.18% or -$0.17 in intraday trading. The EVAX share’s 52-week high remains $23.70, putting it -818.6% down since that peak but still an impressive 13.95% since price per share fell to its 52-week low of $2.22. The company has a valuation of $3.02M, with an average of 13.13 million shares in intraday trading volume over the past 10 days and average of 2.31 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Evaxion Biotech A/S ADR (EVAX), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give EVAX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.03.

Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information

After registering a -6.18% downside in the last session, Evaxion Biotech A/S ADR (EVAX) has traded red over the past five days. The 5-day price performance for the stock is 5.09%, and -43.61% over 30 days. With these gigs, the year-to-date price performance is -38.96%. Short interest in Evaxion Biotech A/S ADR (NASDAQ:EVAX) saw shorts transact 0.1 million shares and set a 1.07 days time to cover.

Revenue forecast for the current quarter as set by 2 analysts is 1.66M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 3.2M.

EVAX Dividends

Evaxion Biotech A/S ADR has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Going by data provided on Nov 30, 2024 , Fidelity NASDAQ Composite Index Fund holds roughly 670.0 shares. This is just over 0.01% of the total shares, with a market valuation of $1728.0